Table 2.

Comparative overview of orphan medical device regulation in the EU and the US.

Dimension	European Union (EU MDR 2017/745)	United States (HUD/HDE framework)
Legal status	No formal orphan-device designation	Legally codified orphan-device category (≤8,000/year)
Evidentiary standard	“Expected clinical benefit” (full CE-marking requirements)	“Probable benefit” (reduced evidentiary threshold)
Flexibility mechanism	Exceptional derogations (Art. 59, Art. 5(5)); non-binding MDCG 2024–10 guidance	Statutory humanitarian pathway under the Safe Medical Devices Act
Financial incentives	None (no fee waivers, no exclusivity)	Profit permitted for pediatric uses; annual distribution cap
Oversight	Decentralized (Notified Bodies, national authorities)	Centralized FDA oversight with IRB supervision
Policy philosophy	Interpretive flexibility within rigid law	Codified flexibility balancing access and safeguards
Systemic consequence	Fragmented access, limited viability	Predictable early access, structured incentives